User:Croissanttabletennis/sandbox

Welcome to your sandbox!

Link to Project Resource Page
Project Homepage and Resources

Practice Editing Here (Nov 23rd in-class Wiki session work)

 * Amyloidosis.

Assignment # 3
Controversies: Given the wide variety of treatments currently undergoing development to treat AL amyloidosis, each therapy gives a slightly different overall survival (median years). In order to proceed forward with this information and making it as digestible as possible for the average reader, I used the numbers that were most highly representative of the therapies that were used as treatments for each stage, e.g. there is data on CyBorD, BMDex, and MDex being used in stage II patients and their overall survival (median years) was 5 years, 53% at 5 years, and 7.4 years. Given this data will continue to evolve more data is generated, I decided to use 5 years as the most accurate estimate of what an average person receiving treatment for a given stage of amyloidosis could expect. Critique of the Source: Both of the sources that I used for the proposed edits are more recent than the current sources used in the section. Both sources are secondary and published by reputable sources, the Journal of the American College of Cardiology and by the American Society of Hematology, respectively, and neither of which are heavily reliant on the results from a single study. Both articles solely address AL amyloidosis and one specifically focuses on just AL cardiac amyloidosis, meaning that the information and results that are presented in my edits do not represent all the amyloidosis subtypes. However given the large number of subtypes and high amount of variation between their prognoses, I determined that it would be important to only produce information concerning one of the more frequent subtypes. Given that ⅓ of patients diagnosed with AL amyloidosis experience symptoms related to their heart, I thought that the information concerning median survival was applicable and generally representative of many cases of AL amyloidosis.
 * Jonah Moore - Proposed Wikipedia Edits 2020-11-28 Original  Prognosis varies with the type of amyloidosis. Prognosis for untreated AL amyloidosis is poor, with median survival of one to two years. More specifically, AL amyloidosis can be classified as stage I, II or III based on cardiac biomarkers like troponin and BNP. Survival diminishes with increasing stage, with estimated survival of 26, 11 and 3.5 months at stages I, II and III, respectively.  Proposed Edits  Prognosis varies with the type of amyloidosis and the affected organ system. Prognosis for untreated AL cardiac amyloidosis is poor, with a median survival of six months. More specifically, AL amyloidosis can be classified as stage I, II or III based on cardiac biomarkers like Nt-proBNP and cardiac troponin.  Survival diminishes with increasing stage, however recent advancements in treatments have improved median survival rates for stages I, II, and III, to 91.2, 60, and 7 months respectively.  Rationale for proposed change:  The original statement regarding how prognosis of amyloidosis is different for each type of amyloidosis should also take into consideration how prognosis can change depending on what organ systems are primarily affected. For the second proposed change, N-terminal prohormone BNP (NT-proBNP) has been demonstrated to be a more robust marker for amyloidosis than BNP and a highly useful prognostic determinant. For my final proposed change, recent estimates for AL cardiac amyloidosis seemed to have narrowed the range for median survival of untreated cases to around 6 months, but I believe that it is worth mentioning how therapeutic  advancements have altered disease progression and its effects on survival. There are now many therapies being developed and including this information in the paragraph modernizes and gives a more in-depth look at prognosis for individuals' looks today.  The information comes from these sources:
 * Merlini, G. (2017). AL amyloidosis: from molecular mechanisms to targeted therapies. Hematology 2014, the American Society of Hematology Education Program Book, 2017(1), 1-12.
 * Falk, R. H., Alexander, K. M., Liao, R., & Dorbala, S. (2016). AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. Journal of the American College of Cardiology, 68(12), 1323-1341.

What to post on the Wikipedia article talk page?

 * This will also be covered on Nov 23rd in class. Your group should use the below template to share an outline of your proposed improvements (including your new wording and citations). Article talk pages are not places to share your assignment answers. The Wikipedia community will be more interested in viewing your exact article improvement suggestions including where you plan to improve the article (which section), what wording you suggest, and the exact citation (Note: all citations must meet WP:MEDRS)
 * You will not be able to paste citations directly from your sandbox to talk pages (unless you are interested in editing/learning Wiki-code in the "source editing" mode). We suggest re-adding your citations on the talk page manually (using the cite button and populating the citation by pasting in the DOI, website, or PMID). You will have to repeat this process yet again when you edit the actual article live.
 * Talk Page Template: CARL Medical Editing Initiative/Fall 2020/Talk Page Template